What is the recommended treatment for chicken pox (varicella)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Chicken Pox (Varicella)

For chicken pox (varicella), oral acyclovir is the recommended treatment, particularly for patients at higher risk for moderate to severe disease. 1, 2

Treatment Recommendations by Patient Population

Children

  • For children 2 years and older: Oral acyclovir 20 mg/kg per dose 4 times daily (80 mg/kg/day) for 5 days 3
  • Children over 40 kg should receive the adult dose 3
  • Treatment should be initiated within 24 hours of rash onset for maximum effectiveness 1, 4

Adults and Children over 40 kg

  • Oral acyclovir 800 mg 4 times daily for 5 days 3
  • Five days of therapy is sufficient as studies show a 7-day course provides no additional benefit 4

High-Risk Populations

  • Acyclovir should be considered for patients at increased risk for moderate to severe varicella, including: 1
    • Persons aged >12 years
    • Persons with chronic cutaneous or pulmonary disorders
    • Persons receiving long-term salicylate therapy
    • Persons receiving short, intermittent, or aerosolized courses of corticosteroids

Immunocompromised Patients

  • Intravenous acyclovir is indicated for varicella-zoster infections in immunocompromised patients 3, 5
  • For HIV-infected children in CDC class 1 with CD4 T-lymphocyte percentage ≥15%, varicella vaccine should be considered rather than treatment after exposure 1

Pregnant Women

  • For pregnant women with serious varicella complications, intravenous acyclovir should be considered 1, 2
  • Acyclovir is classified as a Category B drug in pregnancy 1, 3
  • A registry of infants whose mothers received systemic acyclovir during the first trimester showed no increased rate of birth defects 1, 2

Clinical Considerations

Timing of Treatment

  • Treatment should be initiated at the earliest sign or symptom of chickenpox 3
  • Maximum effectiveness is achieved when acyclovir is administered within 24 hours of rash onset 1, 4
  • There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms 3
  • However, some benefit has been observed when treatment is started within 48 hours of rash onset 4

Benefits of Treatment

  • Acyclovir reduces the number of lesions and shortens the duration of new lesion formation 6
  • Treatment decreases fever duration and severity of cutaneous and systemic symptoms 1
  • Patients begin to feel better sooner with fewer systemic signs and symptoms (fever, fatigue, loss of appetite) 6

Limitations of Treatment

  • Acyclovir does not decrease transmission of varicella 1
  • It does not reduce the duration of absence from school 1

Post-Exposure Prophylaxis

For Immunocompromised Individuals

  • Varicella-Zoster Immune Globulin (VZIG) is recommended for susceptible immunocompromised patients within 96 hours of exposure 1, 2

For Healthy Individuals

  • Vaccination is the method of choice for post-exposure prophylaxis in healthy individuals without evidence of immunity 1

Special Considerations

Renal Impairment

  • Dose adjustment is necessary for patients with renal impairment 3
  • For creatinine clearance 10-25 mL/min/1.73m², 800 mg acyclovir should be given every 8 hours 3
  • For creatinine clearance <10 mL/min/1.73m², 800 mg acyclovir should be given every 12 hours 3

Hydration

  • Adequate hydration should be maintained during acyclovir treatment 3

Viral Resistance

  • Studies have shown that viruses shed during therapy remained susceptible to acyclovir and retained normal thymidine kinase function 4

Common Pitfalls and Caveats

  • Delaying treatment beyond 24 hours significantly reduces efficacy 1, 4
  • Acyclovir is not routinely recommended for all healthy children with chickenpox due to minimal morbidity and mortality in this population 6
  • Symptomatic treatment alone is usually adequate for uncomplicated chickenpox in immunocompetent individuals 7
  • Antiviral therapy does not eliminate the risk of latent virus reactivation (herpes zoster/shingles) later in life 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Varicella

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Antiviral treatment in chickenpox and herpes zoster.

Journal of the American Academy of Dermatology, 1988

Research

Acyclovir in the treatment of chickenpox.

Pediatric nursing, 1992

Research

Therapeutic approach to chickenpox in children and adults--our experience.

Medical archives (Sarajevo, Bosnia and Herzegovina), 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.